-
1
-
-
0036176161
-
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
-
National Kidney Foundation
-
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
-
(2002)
Am J Kidney Dis
, vol.39
, Issue.2 SUPPL. 1
-
-
-
2
-
-
35848968871
-
Prevalence of chronic kidney disease in the United States
-
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
-
(2007)
JAMA
, vol.298
, Issue.17
, pp. 2038-2047
-
-
Coresh, J.1
Selvin, E.2
Stevens, L.A.3
-
3
-
-
76749087371
-
Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP)
-
Stevens LA, Li S, Wang C, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3 suppl 2): S23-S33.
-
(2010)
Am J Kidney Dis
, vol.55
, Issue.3 SUPPL. 2
-
-
Stevens, L.A.1
Li, S.2
Wang, C.3
-
4
-
-
20544467918
-
Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999
-
Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489-495.
-
(2005)
J Am Soc Nephrol
, vol.16
, Issue.2
, pp. 489-495
-
-
Foley, R.N.1
Murray, A.M.2
Li, S.3
-
5
-
-
40449090625
-
-
United States Renal Data System, Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services
-
United States Renal Data System. 2007 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services; 2007.
-
(2007)
2007 Annual Data Report
-
-
-
6
-
-
33845760213
-
KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
-
Kidney Disease Outcomes Quality Initiative (KDOQI)
-
Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 suppl 2): S12-S154.
-
(2007)
Am J Kidney Dis
, vol.49
, Issue.2 SUPPL. 2
-
-
-
7
-
-
78651338445
-
Standards of medical care in diabetes-2011
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 1
-
-
-
8
-
-
58149301489
-
Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
-
American Diabetes Association; American College of Cardiology Foundation; American Heart Association
-
Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009; 53(3):298-304.
-
(2009)
J Am Coll Cardiol
, vol.53
, Issue.3
, pp. 298-304
-
-
Skyler, J.S.1
Bergenstal, R.2
Bonow, R.O.3
-
9
-
-
77955585592
-
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial
-
ACCORD trial group, published correction appears in Lancet. 2010;376(9751):1466
-
Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [published correction appears in Lancet. 2010;376(9751):1466]. Lancet. 2010;376(9739):419-430.
-
(2010)
Lancet
, vol.376
, Issue.9739
, pp. 419-430
-
-
Ismail-Beigi, F.1
Craven, T.2
Banerji, M.A.3
-
10
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
ADVANCE Collaborative Group
-
Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
-
(2008)
N Engl J Med
, vol.358
, Issue.24
, pp. 2560-2572
-
-
Patel, A.1
Macmahon, S.2
Chalmers, J.3
-
11
-
-
0037968349
-
Guidelines for improving the care of the older person with diabetes mellitus
-
California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes, guidelines
-
Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 suppl guidelines):S265-S280.
-
(2003)
J Am Geriatr Soc
, vol.51
, Issue.5 SUPPL
-
-
Brown, A.F.1
Mangione, C.M.2
Saliba, D.3
Sarkisian, C.A.4
-
12
-
-
46449117004
-
The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis
-
Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med. 2008;149(1):11-19.
-
(2008)
Ann Intern Med
, vol.149
, Issue.1
, pp. 11-19
-
-
Huang, E.S.1
Zhang, Q.2
Gandra, N.3
Chin, M.H.4
Meltzer, D.O.5
-
13
-
-
75849147039
-
Relation between kidney function, proteinuria, and adverse outcomes
-
Alberta Kidney Disease Network
-
Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423-429.
-
(2010)
JAMA
, vol.303
, Issue.5
, pp. 423-429
-
-
Hemmelgarn, B.R.1
Manns, B.J.2
Lloyd, A.3
-
14
-
-
77953291706
-
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis
-
Chronic Kidney Disease Prognosis Consortium
-
Matsushita K, van der Velde M, Astor BC, et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
-
(2010)
Lancet
, vol.375
, Issue.9731
, pp. 2073-2081
-
-
Matsushita, K.1
van der Velde, M.2
Astor, B.C.3
-
15
-
-
3042819708
-
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
-
Kidney Disease Outcomes Quality Initiative (K/DOQI)
-
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 1):S1-S290.
-
(2004)
Am J Kidney Dis
, vol.43
, Issue.5 SUPPL. 1
-
-
-
16
-
-
38049139424
-
Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease
-
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48.
-
(2008)
Ann Intern Med
, vol.148
, Issue.1
, pp. 30-48
-
-
Kunz, R.1
Friedrich, C.2
Wolbers, M.3
Mann, J.F.4
-
17
-
-
0027517659
-
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
-
published correction appars in N Engl J Med. 1993;330(2):152, The Collaborative Study Group
-
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published correction appars in N Engl J Med. 1993;330(2):152]. N Engl J Med. 1993;329(20):1456-1462.
-
(1993)
N Engl J Med
, vol.329
, Issue.20
, pp. 1456-1462
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Bain, R.P.3
Rohde, R.D.4
-
18
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Collaborative Study Group
-
Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
-
(2001)
N Engl J Med
, vol.345
, Issue.12
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
-
19
-
-
0035902622
-
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
-
published correction appears in Ann Intern Med. 2002;137(4):299
-
Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data [published correction appears in Ann Intern Med. 2002;137(4):299]. Ann Intern Med. 2001;135(2):73-87.
-
(2001)
Ann Intern Med
, vol.135
, Issue.2
, pp. 73-87
-
-
Jafar, T.H.1
Schmid, C.H.2
Landa, M.3
-
20
-
-
66149192531
-
Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: Is the evidence base relevant to older adults?
-
O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150(10):717-724.
-
(2009)
Ann Intern Med
, vol.150
, Issue.10
, pp. 717-724
-
-
O'Hare, A.M.1
Kaufman, J.S.2
Covinsky, K.E.3
Landefeld, C.S.4
McFarland, L.V.5
Larson, E.B.6
-
21
-
-
0035203597
-
ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy
-
Gruppo Italiano di Studi Epidemiologici in Nefrologia
-
Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001;12(12):2832-2837.
-
(2001)
J Am Soc Nephrol
, vol.12
, Issue.12
, pp. 2832-2837
-
-
Ruggenenti, P.1
Perna, A.2
Remuzzi, G.3
-
22
-
-
30444452987
-
Efficacy and safety of benazepril for advanced chronic renal insufficiency
-
Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2): 131-140.
-
(2006)
N Engl J Med
, vol.354
, Issue.2
, pp. 131-140
-
-
Hou, F.F.1
Zhang, X.2
Zhang, G.H.3
-
23
-
-
0034627208
-
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
-
Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
-
(2000)
BMJ
, vol.321
, Issue.7274
, pp. 1440-1444
-
-
Mogensen, C.E.1
Neldam, S.2
Tikkanen, I.3
-
24
-
-
49149087718
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
-
ONTARGET investigators
-
Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
-
(2008)
Lancet
, vol.372
, Issue.9638
, pp. 547-553
-
-
Mann, J.F.1
Schmieder, R.E.2
McQueen, M.3
-
25
-
-
0038460302
-
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report
-
National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee, published correction appears in JAMA. 2003;290(2):197
-
Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA. 2003;289(19):2560-2572.
-
(2003)
JAMA
, vol.289
, Issue.19
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
27
-
-
79955375480
-
Systematic review: Blood pressure target in chronic kidney disease and proteinuria as an effect modifier
-
Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541-548.
-
(2011)
Ann Intern Med
, vol.154
, Issue.8
, pp. 541-548
-
-
Upadhyay, A.1
Earley, A.2
Haynes, S.M.3
Uhlig, K.4
-
28
-
-
67649426365
-
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
-
Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(2):CD007784.
-
(2009)
Cochrane Database Syst Rev
, Issue.2
-
-
Navaneethan, S.D.1
Pansini, F.2
Perkovic, V.3
-
29
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
-
SHARP Investigators
-
Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
-
(2011)
Lancet
, vol.377
, Issue.9784
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
-
30
-
-
0037379751
-
K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease
-
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
-
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 suppl 3):I-IV, S1-S91.
-
(2003)
Am J Kidney Dis
, vol.41
, Issue.4 SUPPL. 3
-
-
-
31
-
-
0035873251
-
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial
-
Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134(10):931-940.
-
(2001)
Ann Intern Med
, vol.134
, Issue.10
, pp. 931-940
-
-
Hunt, D.1
Young, P.2
Simes, J.3
-
32
-
-
77958577146
-
Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds
-
Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing. 2010;39(6):674-680.
-
(2010)
Age Ageing
, vol.39
, Issue.6
, pp. 674-680
-
-
Petersen, L.K.1
Christensen, K.2
Kragstrup, J.3
-
33
-
-
32944454579
-
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients
-
Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005;(3):CD003266.
-
(2005)
Cochrane Database Syst Rev
, Issue.3
-
-
Cody, J.1
Daly, C.2
Campbell, M.3
-
34
-
-
34548046760
-
KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target
-
Kidney Disease Outcomes Quality Initiative (KDOQI)
-
Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
-
(2007)
Am J Kidney Dis
, vol.50
, Issue.3
, pp. 471-530
-
-
-
36
-
-
33750983605
-
Correction of anemia with epoetin alfa in chronic kidney disease
-
CHOIR Investigators
-
Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
-
(2006)
N Engl J Med
, vol.355
, Issue.20
, pp. 2085-2098
-
-
Singh, A.K.1
Szczech, L.2
Tang, K.L.3
-
37
-
-
33751002326
-
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
-
CREATE Investigators
-
Drüeke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
-
(2006)
N Engl J Med
, vol.355
, Issue.20
, pp. 2071-2084
-
-
Drüeke, T.B.1
Locatelli, F.2
Clyne, N.3
-
38
-
-
70949108082
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
-
TREAT Investigators
-
Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
-
(2009)
N Engl J Med
, vol.361
, Issue.21
, pp. 2019-2032
-
-
Pfeffer, M.A.1
Burdmann, E.A.2
Chen, C.Y.3
-
39
-
-
84455194972
-
FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythopoiesis-stimulating Agents (ESAs) In Chronic Kidney Disease
-
U.S. Food and Drug Administration, Accessed September 1, 2011
-
U.S. Food and Drug Administration. FDA drug safety communication: Modified dosing recommendations to improve the safe use of erythopoiesis-stimulating agents (ESAs) in chronic kidney disease. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed September 1, 2011.
-
-
-
-
40
-
-
33745283670
-
Prophylaxis strategi es for contrast-induced nephropathy
-
Alberta Kidney Disease Network
-
Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis strategi es for contrast-induced nephropathy. JAMA. 2006; 295(23):2765-2779.
-
(2006)
JAMA
, vol.295
, Issue.23
, pp. 2765-2779
-
-
Pannu, N.1
Wiebe, N.2
Tonelli, M.3
-
41
-
-
0030661687
-
Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality
-
McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368-375.
-
(1997)
Am J Med
, vol.103
, Issue.5
, pp. 368-375
-
-
McCullough, P.A.1
Wolyn, R.2
Rocher, L.L.3
Levin, R.N.4
O'Neill, W.W.5
-
42
-
-
4644296839
-
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation
-
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-1399.
-
(2004)
J Am Coll Cardiol
, vol.44
, Issue.7
, pp. 1393-1399
-
-
Mehran, R.1
Aymong, E.D.2
Nikolsky, E.3
-
43
-
-
33747890431
-
Risk prediction of contrast-induced nephropathy
-
CIN Consensus Working Panel
-
McCullough PA, Adam A, Becker CR, et al.; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):27K-36K.
-
(2006)
Am J Cardiol
, vol.98
, Issue.6 A
-
-
McCullough, P.A.1
Adam, A.2
Becker, C.R.3
-
44
-
-
31344440606
-
Clinical practice. Preventing nephropathy induced by contrast medium
-
Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379-386.
-
(2006)
N Engl J Med
, vol.354
, Issue.4
, pp. 379-386
-
-
Barrett, B.J.1
Parfrey, P.S.2
-
45
-
-
68749089747
-
High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy
-
Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med. 2009;122(9):874.e9-e15.
-
(2009)
Am J Med
, vol.122
, Issue.9
-
-
Trivedi, H.1
Daram, S.2
Szabo, A.3
Bartorelli, A.L.4
Marenzi, G.5
-
46
-
-
78049252959
-
Strategies for the prevention of contrast-induced acute kidney injury
-
Weisbord SD, Palevsky PM. Strategies for the prevention of contrast-induced acute kidney injury. Curr Opin Nephrol Hypertens. 2010;19(6):539-549.
-
(2010)
Curr Opin Nephrol Hypertens
, vol.19
, Issue.6
, pp. 539-549
-
-
Weisbord, S.D.1
Palevsky, P.M.2
-
47
-
-
66849141052
-
Current status of gadolinium toxicity in patients with kidney disease
-
published correction appears in Clin J Am Soc Nephrol. 2009;4(4):866
-
Perazella MA. Current status of gadolinium toxicity in patients with kidney disease [published correction appears in Clin J Am Soc Nephrol. 2009;4(4):866]. Clin J Am Soc Nephrol. 2009;4(2):461-469.
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, Issue.2
, pp. 461-469
-
-
Perazella, M.A.1
-
48
-
-
73649090430
-
NSF prevention in clinical practice: Summary of recommendations and guidelines in the United States, Canada, and Europe
-
Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging. 2009;30(6):1357-1363.
-
(2009)
J Magn Reson Imaging
, vol.30
, Issue.6
, pp. 1357-1363
-
-
Leiner, T.1
Kucharczyk, W.2
|